Results 21 to 30 of about 29,467 (290)

SHARED: An International Collaboration to Unravel Hepatitis C Resistance

Viruses, 2021
The advent of direct-acting antivirals (DAAs) has transformed the treatment landscape of hepatitis C [...]
Anita Y.M. Howe, Francesca Ceccherini-Silberstein, Julia Dietz, Stephanie Popping, Jason Grebely, Chaturaka Rodrigo, Johan Lennerstrand, Mark W. Douglas, Milosz Parczewsk, P. Richard Harrigan, Jean-Michel Pawlotsky, Federico Garcia, SHARED Collaborators   +12 more
doaj   +1 more source

Direct-acting antivirals for chronic hepatitis C [PDF]

Cochrane Database of Systematic Reviews, 2016
Millions of people worldwide suffer from hepatitis C, which can lead to severe liver disease, liver cancer, and death. Direct-acting antivirals (DAAs) are relatively new and expensive interventions for chronic hepatitis C, and preliminary results suggest that DAAs may eradicate hepatitis C virus (HCV) from the blood (sustained virological response ...
Jakobsen, Janus C., Nielsen, Eric, Feinberg, Jesicca, Katakam, K, Fobian, K, Hauser, Goran, Poropat, Goran, Djurišić, Snežana, Weiss, K, Bjelaković, Milica, Bjelaković, Goran, Klingenberg, Sarah, Liu, J, Nikolova, Dimitrinka, Koretz, Ronald, Gluud, Christian   +15 more
openaire   +8 more sources

Hepatitis C virus resistance to the new direct-acting antivirals [PDF]

, 2016
Introduction: The treatment of hepatitis C virus (HCV) infection has dramatically improved in recent years with the widespread use of interferon-free combination regimens.
Esposito, Isabella, Soriano, Vicente, Trinks, Julieta   +2 more
core   +1 more source

Therapeutic Advances Against ZIKV: A Quick Response, a Long Way to Go

Pharmaceuticals, 2019
Zika virus (ZIKV) is a mosquito-borne flavivirus that spread throughout the American continent in 2015 causing considerable worldwide social and health alarm due to its association with ocular lesions and microcephaly in newborns, and Guillain−Barr&
Juan-Carlos Saiz
doaj   +1 more source

Therapeutic developments for SARS-CoV-2 infection—Molecular mechanisms of action of antivirals and strategies for mitigating resistance in emerging variants in clinical practice

Frontiers in Microbiology, 2023
This article systematically presents the current clinically significant therapeutic developments for the treatment of COVID-19 by providing an in-depth review of molecular mechanisms of action for SARS-CoV-2 antivirals and critically analyzing the ...
Oana Săndulescu, Oana Săndulescu, Cătălin Gabriel Apostolescu, Cătălin Gabriel Apostolescu, Liliana Lucia Preoțescu, Liliana Lucia Preoțescu, Adrian Streinu-Cercel, Adrian Streinu-Cercel, Mihai Săndulescu   +8 more
doaj   +1 more source

Neuropsychiatric performance and treatment of hepatitis C with direct-acting antivirals: a prospective study [PDF]

, 2017
Background: Since direct-acting antivirals (DAAs) have been approved for the treatment of hepatitis C virus (HCV) infection, a small series of patients with new-onset neuropsychiatric alterations have been referred to us.
Amodio, Piero, Burra, Patrizia, De Rui, Michele, Ferrarese, Alberto, Gambato, Martina, Germani, Giacomo, Montagnese, Sara, Russo, Francesco Paolo, Senzolo, Marco, Turco, Matteo, Volpato, Sofia, Zanetto, Alberto   +11 more
core   +1 more source

Synergistic In Vitro Antiviral Effect of Combinations of Ivermectin, Essential Oils, and 18-(Phthalimid-2-yl)ferruginol against Arboviruses and Herpesvirus

Pharmaceuticals, 2023
Combining antiviral drugs with different mechanisms of action can help prevent the development of resistance by attacking the infectious agent through multiple pathways.
Liliana Betancur-Galvis, Orlando José Jimenez-Jarava, Fatima Rivas, William E. Mendoza-Hernández, Miguel A. González-Cardenete   +4 more
doaj   +1 more source

The evaluation of liver fibrosis regression in chronic hepatitis C patients after the treatment with direct-acting antiviral agents – A review of the literature [PDF]

, 2019
The second-generation of direct-acting antiviral agents are the current treatment for chronic viral hepatitis C infection. To evaluate the regression of liver fibrosis in patients receiving this therapy, liver biopsy remains the most accurate method, but
Alexescu, Teodora G, Cibu, Bianca A, Ciulei, George, Coste, Sorina C, Cozma, Angela, Mureșan, Flaviu, Negrean, Vasile, Orasan, Olga H, Ovidiu, Fabian, Pfingstgraf, Iulia O, Popovici, Ionela E, Tarmure, Simina F, Taut, Adela V. S   +12 more
core   +3 more sources

Hepatitis C Virus and Hepatocellular Carcinoma: Pathogenetic Mechanisms and Impact of Direct-Acting Antivirals [PDF]

, 2018
INTRODUCTION: Globally, between 64 and 103 million people are chronically infected with Hepatitis C virus (HCV), with more than 4.6 million people in the United States and is associated with more than 15.000 deaths annually.
Petruzziello, Arnolfo, Pinacchio, Claudia, Scheri, Giuseppe Corano, Schietroma, Ivan, Statzu, Maura, Vullo, Vincenzo   +5 more
core   +1 more source

Broad-Spectrum Antivirals Derived from Natural Products

Viruses, 2023
Scientific advances have led to the development and production of numerous vaccines and antiviral drugs, but viruses, including re-emerging and emerging viruses, such as SARS-CoV-2, remain a major threat to human health.
Wen-Jun Tian, Xiao-Jia Wang
doaj   +1 more source